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RESULTS: At a threshold of $100,000/QALY, the CEAC for PSA1 showed a 97% prob-
ability that TxB is cost-effective versus TxA, corresponding results for PSA2, and
PSA3, were 54%, and 58%, respectively. CONCLUSIONS: Failure to consider uncer-
tainties owing to PFS/OS data in oncology models, and to the ensuing calibration
procedures, can lead to under-representation of uncertainty in cost-effectiveness
results.
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MODELING THE LIFETIME EFFECTIVENESS OF DENOSUMAB AND ZOLEDRONIC
ACID (ZA) IN THE PREVENTION OF SKELETAL RELATED EVENTS (SRE) IN
PATIENTS WITH BONE METASTASES FROM SOLID TUMORS
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OBJECTIVES: Because bone metastases can cause costly SREs, lifetime estimates of
SREs prevented can help payers compare the effectiveness of treatment options. De-
nosumab was recently approved in the US for SRE prevention in patients with bone
metastases from solid tumors. This study presents amodel for SRE predictions based
on phase III trials comparing denosumab and ZA in different tumors. METHODS: A
three-state Markov model (On Treatment, Off Treatment, and Dead) was developed
using constant SRE incidence rates for each tumor type and treatment. Results were
comparedbetween themodeland trial for the3-year trial durationandextrapolated to
the patient lifetime. Lifetime SREs were estimated for the US population based on the
estimated annual number of newpatientswith bonemetastases.Mortality rateswere
identical between treatments and estimated using trial-based generalized gamma
distributions. Lifetime treatment was assumed. RESULTS: The number of all SREs
observed (rateper patient-year) for denosumabandZAwere 660 (0.488) and853 (0.631)
for breast cancer, 780 (0.746) and943 (0.947) for prostate cancer, and469 (0.588) and535
(0.690) for other solid tumors. Comparisonbetween trial results andmodel projections
over the trial time horizon resulted in differences in SRE counts ranging from -1.5% to
2.0%.Over the expectedpatient lifetime, estimatedSREsperpatientwere 1.80 and2.32
(denosumab and ZA) for breast cancer, 1.65 and 2.08 for prostate cancer, and 1.36 and
1.60 for other solid tumors. In annual incident cohorts of patients with bonemetasta-
ses, themodel projects 43,765 and 56,408 (denosumab and ZA) lifetime SREs in breast
cancer and 30,429 and 38,359 lifetime SREs in prostate cancer. CONCLUSIONS: The
model output is consistentwith the clinical trial evidence, and canbeused to compare
estimates of the predicted lifetime SREs for denosumab and ZA.
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ESTIMATING THE EPIDEMIOLOGY OF LATE-STAGE CANCERS – A
MATHEMATICAL APPROACH
Pan F, Sorensen S, Stern S
United BioSource Corporation, Bethesda, MD, USA
OBJECTIVES:Accurate estimates of cancer epidemiology are fundamental to quan-
tifying the economic burden of cancer as well as supporting a variety of researches
in public health and commercial activities. However, the complete prevalence and
incidence of late-stage cancers is difficult to obtain as most surveillance programs
report cases at initial diagnosis, so recurrent cases, by definition are not captured.
The objective of this study is to present a simple mathematical approach to esti-
mate the epidemiology of late-stage cancers. METHODS: We developed an Excel-
based tool to estimate the epidemiology of late-stage cancerswithminimal historic
information. Data needed include annual national or local cancer-relatedmortality
rates, late-stage cancer survival rates and population size. Our approach starts
with the patients who died from the specific cancer and tracks back to estimate the
incidence and prevalence. The approach assumes most deaths attributed to the
cancer are late-stage disease. We tested our approach by estimating the incidence
and prevalence ofmetastatic breast cancer andmetastaticmelanomawith historic
mortality and survival data from the National Cancer Institute Surveillance, Epi-
demiology and End Results (SEER) Program. RESULTS:We estimated that the 2007
US incidence of stage IV breast cancer andmelanomawere approximately 32.4 per
100,000 women and 2.7 per 100,000 persons, respectively. These results corre-
sponded to a total of 49,505 patients (10,426 newly diagnosed and 39,079 recurrent
cases) for stage IV breast cancer and total of 8,279 patients (3,690 newly diagnosed
and 4,589 recurrent cases) for late-stage melanoma. Results are also available by
age and gender groups. CONCLUSIONS: Comparison of results using this epidemi-
ology tool with estimates from databases and chart review studies demonstrated
that our approach is reasonably accurate in its estimation. This approach could be
adopted for uncommon cancers or regions with scarce data.
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OBJECTIVES: Bladder cancer is a commonmalignancy with70,500 incident cases
per year in the US; 70% present as non-muscle invasive bladder cancer (NMIBC).
Perioperative instillation of chemotherapy after transurethral resection of the
bladder (TURBT) can reduce the risk of recurrence. Our objective was to estimate
the loss of quality-adjusted life years (QALY) due to unnecessary recurrences for
patients not receiving perioperative chemotherapy (PC). METHODS: A decision-
treemodel estimated the loss of QALYs following recurrence inNMIBC patients not
receiving PC. Therapy utilization rates were obtained from a chart review study of
1010 NMIBC patients treated by 259 US urologists. In this sample, 17% of patients
received PC after the initial TURBTand 27% received perioperative therapy after the
first recurrence. In addition, 48.6% received induction therapy with BCG (85%) or
mitomycin-C (MMC, 15%) after the first recurrence. The estimated 2-year recur-
rence rates in NMIBC patients were 53% with TURBT alone and 36% with TURBT
and PC. QALY estimates were obtained from literature with disutilities of0.10 for
each resection, 0.026 for BCG therapy, and an assumed 0.01 for MMC therapy.
RESULTS: According to estimates, 49,350 new cases of NMIBC are expected in the
US in 2010; 100% utilization of PC would result in avoidance of 6,962 bladder tumor
recurrences. Themodel estimates that 911 QALYs are lost over a 2-year time period
from preventable recurrences. This equates to 0.02 QALYs for all patients under-
going TURBT. An estimate of disutility at the first recurrence indicates a gain of
nearly 47 quality-adjusted days per avoidable recurrence and 8 days per new
NMIBC case if intravesical PCwas utilized.CONCLUSIONS:A substantial number of
QALYs are lost each year due to underuse of intravesical PC. Increased use of PC
could reduce the humanistic burden of unnecessary recurrences in NMIBC.
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OBJECTIVES: In 2010, an estimated 70,500 new cases of bladder cancer will be
diagnosed in the US; 70% will present as non-muscle invasive bladder cancer
(NMIBC). The instillation of intravesical chemotherapy after transurethral resec-
tion of bladder tumor (TURBT) can reduce the risk of tumor recurrence. The objec-
tive of this study is to estimate the economic consequences associated with un-
necessary recurrences in patients deprived of perioperative chemotherapy (PC).
METHODS: A decision-tree model estimated the economic consequences of recur-
rence in patients not receiving PC. Two sources were used to estimate rates for the
model because neither data source had both of the rates required; 1010 NMIBC
patient charts (from 259 US urologists) estimated therapy utilization, and recur-
rence rates were obtained from 502 patients enrolled in a trial by Tolley, et al.
randomizing patients to mitomycin C (MMC) versus no PC. Costs were estimated
using prevailing Medicare reimbursement rates for TURBT ($1,982), BCG induction
therapy ($201/instillation), MMC induction therapy ($252/instillation) and periop-
erative MMC ($166/instillation). RESULTS: Within the cohort, 17% of patients re-
ceived PC after the initial TURBT. The overall recurrence rate was 39%. At first
recurrence, 27% received PC and 48.6% received induction therapy with BCG (85%)
or MMC (15%). Data from the randomized trial indicate that at 2 years, 36% of
patients receiving PC recur compared with 53% receiving TURBT alone. Population
estimates predict 49,350 new cases of NMIBC in the US in 2010. The model demon-
strated prevention of 6962 bladder recurrenceswith perioperativeMMCafter initial
TURBT, with an estimated savings of $2608 per patient. This translates into aggre-
gate savings of $18.1 million to the US health care system over two years.
CONCLUSIONS: Greater use of PC after TURBT can reduce economic loss related to
preventable bladder tumor recurrences with substantial savings to the health care
system.
PCN136
ESTIMATING UTILITIES IN CANCER: A COMPARISON OF EQ-5D AND
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OBJECTIVES:Although utility-based algorithms have been developed for the Func-
tional Assessment of Cancer Therapy (FACT), their properties are not well-known
compared to more widely used utility measures like the EQ-5D. The objective of
this study was to compare the properties and relationships between EQ-5D and
FACT-based health utility scores in cancer patients. METHODS: A retrospective
analysis was conducted on cross-sectional data collected from 534 cancer patients
who completed both FACT-G and EQ-5D. Properties of scores from 3 FACT-based
and 2 EQ-5D based algorithms were examined. Known groups comparisons were
based on physician and patient-rated ECOGperformance status. Relative efficiency
(RE) of the utility algorithms was examined using ratios of F-statistics. RESULTS:
Mean scores for the overall cohort were lowest using Kind and Macran’s FACT UK
societal (0.55, SD 0.09), followed by Dolan’s EQ-5D UK societal (0.72, SD 0.23),
Cheung et al.’s FACT mapped to EQ-5D (0.74, SD 0.11), Shaw et al.’s EQ-5D US
societal (0.79, SD 0.15), and highest using Dobrez et al’s FACT US patient algorithm
(0.83, SD 0.08). When stratified by ECOG status, the largest differences in mean
scores were generally observed for EQ-5D UK societal scores and smallest for the
FACT-based US patient scores; however, FACT UK societal scores had twice the
statistical efficiency of the other algorithms. CONCLUSIONS:We found important
differences in utilities scores estimated by each algorithm. The FACT-based algo-
rithms tended to underestimate the QALY benefit compared to the EQ-5D, and
appeared to driven by a more limited range of scale.
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COMPREHENSIVE REVIEW OF MANAGEMENT EFFICIENCY STRATEGIES AMONG
ONCOLOGY PRACTICES: EXISTING EVIDENCE AND OPPORTUNITIES FOR
FUTURE RESEARCH
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OBJECTIVES: Faced with decreasing reimbursement costs, greater patient vol-
umes, higher operating costs and pressure to adopt quality standards, community
oncology practices and infusion centers operate in an increasingly challenging
environment. This study sought to assess the practice efficiency techniques cur-
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rently employed and identify opportunities for future research.METHODS: A com-
prehensive literature review of reference databases, conference abstracts, journals
and medical societies’ websites was performed. Publications reporting practice
management efficiency measures within ambulatory oncology practices and infu-
sion centers located in the United States were included. Search was limited to
English-language articles published between 2007 and 2010. All publication types
except continuing medical education materials and letters to the editor were ac-
cepted. Evidence quality was assessed with the Completeness of Reporting index
(CORE-14) instrument. RESULTS: Forty-seven references were accepted for inclu-
sion. Efficiency strategieswere classified into 7 distinct categories, each reported at
a similar frequency in the literature. Within and across these categories, common
themeswere standardization of care, use of best practices, and alignment between
quality and profitability initiatives. Most publications were recommendations
without a study design type (64%) and/or did not report quantifiable outcome data
(74%). Additionally, 21 publications did not define the practice type included, while
the remaining articles identified 12 different practice types. Consequently, appli-
cability is limited, since outcomes cannot be associated with a particular practice
type. Thirty-four publications were assigned a CORE-14 score of 0, indicating they
did not meet any criteria for methodological quality (mean score, 1.84).
CONCLUSIONS: Numerous efficiency methods are being touted in the literature,
but there is limited definitive data on the successfulness of these techniques. Fur-
ther research, of a high methodological caliber, is needed to support informed
decisions. Specifically, registries, surveys, and economic analyses would empower
oncologists and other oncology professionals with practical strategies to concur-
rently improve quality while maintaining profitability.
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A REVIEW OF EXPANDED ACCESS PROGRAMS (EAP) AND THEIR
CONSIDERATION BY HEALTH PLAN DECISION-MAKERS IN THE UNITED STATES
Khurdayan V, Rizzo M, Darity A, Mun D
Double Helix Consulting, New York, NY, USA
OBJECTIVES: After failing approved treatments, patients may receive investiga-
tional therapies through participation in a clinical trial or an expanded access
program (EAP). EAPs were established after the FDA decided to allow patients ac-
cess to investigational drugs for treatment purposes, and since then EAPs have
been set up in various therapeutic areas including oncology and infectious dis-
eases. No analysis, however, has been completed evaluating the use and value of
EAP data to US payers.METHODS:We analyzed the impact of EAP data on the US
payer decision making process in drug formulary positioning. Using examples of
different types of drug data including EAP, payers were asked how each type af-
fected drug coverage. After reviewing these results, we assessed payers’ awareness
of EAP relative to other data types to determine future impacts of EAP. Our study
allowed us to define the key value drivers for EAP trials and construct a value
matrix to evaluate future EAP opportunities. RESULTS: Payers in the United States
had a low awareness of EAP data driven by a lack of exposure to the data type but
mostly attributed to their sole use of RCT data in formulary decisions. While most
payers agreed that EAP data has little influence on their decision making process,
they did highlight factors that make EAP data more valuable to other stakeholders
and discussed how EAP data could improve product perception. CONCLUSIONS:
Our findings suggest that payers will not change their management approach and
formulary decisions based on EAP data. Payers realize that EAP datamight bemore
representative of the real world patient population than data from RCTs; however,
RCTs will remain the gold standard data source to evaluate agents for reimburse-
ment and formulary placement.
Gastrointestinal Disorders – Clinical Outcomes Studies
PGI1
INCIDENCE OF ANEMIA AND NEUTROPENIA FOLLOWING HCV TREATMENT
INITIATION AND RELATED DRUG TREATMENT COSTS IN THE UNITED STATES
Diels J, Gavart S, Nuyts G
Janssen Pharmaceutica, Beerse, Belgium
OBJECTIVES: Conventional peginterferon-ribavirin antiviral treatment of chronic
hepatitis C virus (HCV) often leads to anemia and neutropenia. Based on US claims
data, we explored the incidence of both adverse events (AEs) and the associated
risk factors, and assessed the related erythropoietin/granulocyte colony stimulat-
ing factor (G-CSF) costs in daily clinical practice.METHODS: Commercially insured
patients with chronic HCV infection (ICD9 070.44,070.54,070.70,070.71) (all geno-
types), who initiated any combination of (peg)interferon and/or ribavirin were
identified in a large US claims database (Thomson 2006–2009). Time to first onset of
anemia and neutropenia was analyzed using Kaplan-Meier and Cox proportional
hazards regression. Anemia and neutropenia were defined based on ICD9-coding
(280-285,288) and/or prescription of erythropoietin and G-CSF. RESULTS: 3,935
chronic HCV-infected patients (mean age 51.1, 63%male) initiated HCV treatment.
86% of the patients initiated a combination of peginterferon and ribavirin. Mean
treatment duration was 245 days. Regardless of time on treatment, 32%/17% of the
cohort experienced anemia/neutropenia respectively. Age, female gender, Charl-
son co-morbidity index and liver cirrhosis were predictive for both AEs. 20.3%/
11.3% of the cohort received erythropoietin/G-CSF treatment respectively, on av-
erage for 131/126 days. Themean cost for the entire cohort tomanage both AEswas
$2,263 (erythropoietin) and $1,004 (G-CSF), which represents 12% of the overall
healthcare cost in the follow-up year for the entire cohort. Themajority of the costs
associated with AE-related treatments (58%/54%) occurred after week 24 of
therapy. CONCLUSIONS: Costs of managing anemia and neutropenia during HCV
treatment are considerable and often continued beyond 24 weeks of treatment.
New HCV treatment combinations allowing to shorten treatment up to 24 weeks,
may considerably reduce AE-related costs. This reduction may be most important
in treatment-naive genotype 1-infected patients, as the standard 48-week treat-
ment duration is longer compared with other genotypes.
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PREDICTORS OF PROTON PUMP INHIBITOR (PPI) DOSING REGIMEN AMONG
PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)
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OBJECTIVES: The aim of this study was to explore the predictors of PPI dosing
regimen [once daily (QD) or twice daily (BID)] among patients with GERD.
METHODS: Using the HealthCore Integrated Research Database from 01/01/2004-
06/30/2009, GERD patients (ICD-9 codes 530.10-530.13, 530.19, 530.81, or 787.1x), 
18 years of age, having at least two PPI pharmacy claims (index date) from 01/01/
2005-06/30/2008 and continuous eligibility for 12months before and after the index
date were identified. Based on the PPI dosing regimen throughout the post-index
period, calculated as the ratio of quantity of medication dispensed/number of days
supply, GERD patients were classified as QD (ratio of 1.5) or BID (ratio of 1.5) PPI
users. Descriptive analyses were used to compare QD vs. BID PPI users and a mul-
tivariate logistic regressionwas conducted to assess independent predictors of BID
PPI use. RESULTS: This study included 248,386 GERD patients with a mean age of
52.8 (13.93) years and 56% were females. Based on the dosing regimen, 90%
(n222,759) were classified as QD and 10% (n25,627) as BID PPI users. Patients
with BID PPI dosing were significantly (all p0.0001) more likely to have Barrett’s
Esophagus (5% vs. 2%), baseline H2RA use (8.7% vs. 6.8%) and higher comorbidity
based on mean Deyo Charlson’s Comorbidity Index score (DCI) [0.89 (SD1.54) vs.
0.70 (SD1.37)]. Logistic regression results demonstrated that females [OR1.13
(95% CI1.08-1.18)], a diagnosis for Barrett’s Esophagus [OR2.08 (95% CI1.84-
2.36)], baseline H2RA [OR1.29 (95% CI1.20-1.39)] or PPI use [OR1.67 (95%
CI1.59-1.74)] and higher DCI score [OR1.09 (95%CI1.08-1.10)] were significant
(all p0.0001) predictors of BID PPI use. CONCLUSIONS: Patients who have a diag-
nosis of Barrett’s Esophagus, had baseline use of PPI or H2RA therapywere found to
be significant predictors of BID PPI dosing. Further studies understanding the dif-
ferences in clinical and economic outcomes based on PPI dosing regimen should be
undertaken.
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THE LIKELIHOOD OF HAVING FUNCTIONAL DYSPEPSIA BASED ON OTHER
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OBJECTIVES:The etiology of functional dyspepsia (FD) is debated. However, limited
published data exist on the associated co-morbid conditions with FD. This study
aimed to assess the odds (likelihood) of having FD based on the presence of other
objectively defined comorbid conditions.METHODS: Retrospective database anal-
ysis on a 4-year study period (2001-2004), using payroll data and adjudicated health
insurancemedical and prescription claims onmore than 300,000 employees. Study
comparisons were performed among employees with FD (ICD9 536.8x) and pro-
pensity-score-matched employees without FD (controls, matched on age, gender,
tenure with employer, marital status, race, region, salary, exempt status, and full-
time/part-time). Comorbid conditions were Specific Conditions (SC) defined by the
Agency for Healthcare Research and Quality (AHRQ). Subjects were classified as
having the condition by any claims with an ICD-9 code for the SC. The likelihood of
being in the FD cohort was modeled using logistic regression with indicator (1/0)
variables for 260 of the 261 specific AHRQ SCs (the FD-SC was not included). Odds
ratios 1.0 indicate the corresponding SC is more likely in the FD cohort, while
ratios1.0 indicate the SC is less likely to be in the FD cohort. RESULTS: The study
dataset contained 85,119 employees (1669 with FD and 83,450 matched controls
without FD). After controlling for all other AHRQ categories, the logistic regression
found that 19 specific categories weremore likely within the FD cohort, and 2 were
less likely within the FD cohort. Esophageal disorders, gastritis and duodenitis,
abdominal pain, and gout were most associated with having FD (odds ratios of 3.8,
3.7, 3.6, and 2.5, respectively). Only hypertension complications/secondary and
disorders of teeth and jaw were significantly negatively associated with FD.
CONCLUSIONS: This study identified varied comorbidities associated with FD di-
agnoses and may aid FD identification in future research.
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PREDICTORS OF HEPATITIS C TREATMENT INITIATION
Wagner JS, Goren A
Kantar Health, New York, NY, USA
OBJECTIVES: Chronic hepatitis C, in its early stages, is commonly asymptomatic,
and many patients do not seek treatment. The current study attempts to identify
the characteristics of hepatitis C patients who initiate treatment for hepatitis C.
METHODS: This study is based on data from the 2009 and 2010 waves of the US
National Health andWellness Survey (N132,478), a cross-sectional database rep-
resentative of the adult US population. Patients who reported having been diag-
nosedwith hepatitis C by a physician were included for analysis (n1279). Patients
currently, or ever, taking a prescription medication for hepatitis C (n579) were
compared with patients who never took a prescription for hepatitis C (n700).
Group membership was predicted with a logistic regression model, including age,
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